PharmaVentures is pleased to announce that it has acted as advisor to one of the top US pharmaceutical companies in its divestment of one of its manufacturing facilities to a US contract manufacturer. The divestment, completed in mid-May, has led to the protection of hundreds of jobs.

This divestment follows PharmaVentures continued success in M&A including the executing of multiple divestments for several of the largest pharmaceutical companies in the world.

Fintan Walton, CEO, PharmaVentures, commented: “Once again we are delighted to have delivered a successful and valuable outcome for our client and in the process secured hundreds of jobs.”

Nigel Borshell, VP, PharmaVentures, who was lead advisor added: “Our network of interested players in contract manufacturing and R&D plus our rigorous sale process has yet again delivered a positive outcome for our client”.

Over the past 23 years, PharmaVentures has acted as advisor to over 700 global pharmaceutical and biotechnology clients in transactions covering licensing, pharma merger, acquisition, divestment and joint venture activities for companies.